KESTRA MEDICAL TECHNOLOGIES (KMTS) Fundamental Analysis & Valuation

NASDAQ:KMTS • BMG524411052

Current stock price

21.14 USD
+1.88 (+9.76%)
At close:
19.27 USD
-1.87 (-8.85%)
After Hours:

This KMTS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. KMTS Profitability Analysis

1.1 Basic Checks

  • KMTS had negative earnings in the past year.
  • In the past year KMTS has reported a negative cash flow from operations.
KMTS Yearly Net Income VS EBIT VS OCF VS FCFKMTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a Return On Assets value of -56.26%, KMTS is not doing good in the industry: 68.48% of the companies in the same industry are doing better.
  • The Return On Equity of KMTS (-84.59%) is worse than 61.41% of its industry peers.
Industry RankSector Rank
ROA -56.26%
ROE -84.59%
ROIC N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMTS Yearly ROA, ROE, ROICKMTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • KMTS has a Gross Margin (46.40%) which is in line with its industry peers.
  • KMTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMTS Yearly Profit, Operating, Gross MarginsKMTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. KMTS Health Analysis

2.1 Basic Checks

  • KMTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KMTS has about the same amout of shares outstanding than it did 1 year ago.
  • The debt/assets ratio for KMTS has been reduced compared to a year ago.
KMTS Yearly Shares OutstandingKMTS Yearly Shares OutstandingYearly Shares Outstanding 2021 2023 2024 2025 10M 20M 30M 40M
KMTS Yearly Total Debt VS Total AssetsKMTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • KMTS has an Altman-Z score of 5.02. This indicates that KMTS is financially healthy and has little risk of bankruptcy at the moment.
  • KMTS has a better Altman-Z score (5.02) than 77.17% of its industry peers.
  • A Debt/Equity ratio of 0.26 indicates that KMTS is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.26, KMTS perfoms like the industry average, outperforming 54.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 5.02
ROIC/WACCN/A
WACC10.25%
KMTS Yearly LT Debt VS Equity VS FCFKMTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • KMTS has a Current Ratio of 5.47. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
  • KMTS's Current ratio of 5.47 is fine compared to the rest of the industry. KMTS outperforms 78.80% of its industry peers.
  • KMTS has a Quick Ratio of 5.47. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of KMTS (5.47) is better than 82.61% of its industry peers.
Industry RankSector Rank
Current Ratio 5.47
Quick Ratio 5.47
KMTS Yearly Current Assets VS Current LiabilitesKMTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. KMTS Growth Analysis

3.1 Past

  • The earnings per share for KMTS have decreased strongly by -46.20% in the last year.
  • Looking at the last year, KMTS shows a very strong growth in Revenue. The Revenue has grown by 62.05%.
EPS 1Y (TTM)-46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.41%
Revenue 1Y (TTM)62.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%53.4%

3.2 Future

  • KMTS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.65% yearly.
  • The Revenue is expected to grow by 46.35% on average over the next years. This is a very strong growth
EPS Next Y-5.13%
EPS Next 2Y0.39%
EPS Next 3Y8.65%
EPS Next 5YN/A
Revenue Next Year56.09%
Revenue Next 2Y51.44%
Revenue Next 3Y49.38%
Revenue Next 5Y46.35%

3.3 Evolution

KMTS Yearly Revenue VS EstimatesKMTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M 250M
KMTS Yearly EPS VS EstimatesKMTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. KMTS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KMTS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KMTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMTS Price Earnings VS Forward Price EarningsKMTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMTS Per share dataKMTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.39%
EPS Next 3Y8.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KMTS Dividend Analysis

5.1 Amount

  • KMTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KMTS Fundamentals: All Metrics, Ratios and Statistics

KESTRA MEDICAL TECHNOLOGIES

NASDAQ:KMTS (3/17/2026, 8:27:47 PM)

After market: 19.27 -1.87 (-8.85%)

21.14

+1.88 (+9.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-17
Earnings (Next)N/A
Inst Owners50.23%
Inst Owner ChangeN/A
Ins Owners0.89%
Ins Owner Change-4.02%
Market Cap1.23B
Revenue(TTM)74.26M
Net Income(TTM)-138.79M
Analysts86.15
Price Target29.58 (39.92%)
Short Float %9.82%
Short Ratio9.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.12%
Min EPS beat(2)-5.83%
Max EPS beat(2)42.08%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.55%
Min Revenue beat(2)6.25%
Max Revenue beat(2)6.85%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.2%
EPS NY rev (1m)-0.07%
EPS NY rev (3m)-2.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.61
P/FCF N/A
P/OCF N/A
P/B 7.52
P/tB 7.52
EV/EBITDA N/A
EPS(TTM)-2.76
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-1.95
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS1.27
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.26%
ROE -84.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.4%
FCFM N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 330.87%
Cap/Sales 36.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.47
Quick Ratio 5.47
Altman-Z 5.02
F-Score5
WACC10.25%
ROIC/WACCN/A
Cap/Depr(3y)226.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)88.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.41%
EPS Next Y-5.13%
EPS Next 2Y0.39%
EPS Next 3Y8.65%
EPS Next 5YN/A
Revenue 1Y (TTM)62.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%53.4%
Revenue Next Year56.09%
Revenue Next 2Y51.44%
Revenue Next 3Y49.38%
Revenue Next 5Y46.35%
EBIT growth 1Y-66.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.3%
EBIT Next 3Y13.57%
EBIT Next 5YN/A
FCF growth 1Y-19.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.44%
OCF growth 3YN/A
OCF growth 5YN/A

KESTRA MEDICAL TECHNOLOGIES / KMTS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KMTS.


What is the valuation status of KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

ChartMill assigns a valuation rating of 0 / 10 to KESTRA MEDICAL TECHNOLOGIES (KMTS). This can be considered as Overvalued.


What is the profitability of KMTS stock?

KESTRA MEDICAL TECHNOLOGIES (KMTS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for KESTRA MEDICAL TECHNOLOGIES?

The Earnings per Share (EPS) of KESTRA MEDICAL TECHNOLOGIES (KMTS) is expected to decline by -5.13% in the next year.